NO863803L - Vaccines and Immunoassays for Acquired Immunodeficiency Syndrome (AIDS). - Google Patents
Vaccines and Immunoassays for Acquired Immunodeficiency Syndrome (AIDS).Info
- Publication number
- NO863803L NO863803L NO863803A NO863803A NO863803L NO 863803 L NO863803 L NO 863803L NO 863803 A NO863803 A NO 863803A NO 863803 A NO863803 A NO 863803A NO 863803 L NO863803 L NO 863803L
- Authority
- NO
- Norway
- Prior art keywords
- vaccines
- htlv
- lav
- acquired immunodeficiency
- iii
- Prior art date
Links
- 208000030507 AIDS Diseases 0.000 title abstract 3
- 238000003018 immunoassay Methods 0.000 title abstract 2
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 206010001513 AIDS related complex Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940031626 subunit vaccine Drugs 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 229960004854 viral vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Rekombinantviruser som styrer uttrykkingen av peptider eller proteiner relatert til epitoper av LAV/HTLV-III, den etiologiske agensen som lympfadenopati-syndromet eller ervervet immunsvikt-syndrom, er beskrevet. Disse virusene kan prepareres som virale vaksiner eller i flerverdige vaksiner som beskytter mot LAV/HTLV-III- infeksjon. Antigeniske peptider og proteiner relatert til epitoper av LAV/HTLV-III er også beskrevet. Disse kan fremstilles ved å anvende rekombinante DNA-tek- nikker eller ved kjemisk syntese, og kan benyttes som immunogene underenhetsvaksiner eller som antigener i diagnostiske immunoanalyser.Recombinant viruses that control the expression of peptides or proteins related to epitopes of LAV / HTLV-III, the etiological agent such as lymphadenopathy syndrome or acquired immunodeficiency syndrome, are described. These viruses can be prepared as viral vaccines or in multifaceted vaccines that protect against LAV / HTLV-III infection. Antigenic peptides and proteins related to LAV / HTLV-III epitopes are also described. These can be prepared using recombinant DNA techniques or chemical synthesis, and can be used as immunogenic subunit vaccines or as antigens in diagnostic immunoassays.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77990985A | 1985-09-25 | 1985-09-25 | |
US84298486A | 1986-03-27 | 1986-03-27 | |
US90521786A | 1986-09-09 | 1986-09-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO863803D0 NO863803D0 (en) | 1986-09-24 |
NO863803L true NO863803L (en) | 1987-03-26 |
Family
ID=27419757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO863803A NO863803L (en) | 1985-09-25 | 1986-09-24 | Vaccines and Immunoassays for Acquired Immunodeficiency Syndrome (AIDS). |
Country Status (22)
Country | Link |
---|---|
CN (1) | CN1020752C (en) |
AT (1) | ATA256786A (en) |
CH (1) | CH676247A5 (en) |
DE (1) | DE3690508T1 (en) |
DK (1) | DK455486A (en) |
ES (2) | ES2002490A6 (en) |
FI (1) | FI863848A (en) |
FR (1) | FR2587720A2 (en) |
GB (1) | GB2181435B (en) |
GR (1) | GR862412B (en) |
HU (1) | HU205780B (en) |
IE (1) | IE59314B1 (en) |
IL (1) | IL80073A (en) |
IT (1) | IT1195829B (en) |
MY (1) | MY103182A (en) |
NL (1) | NL8602422A (en) |
NO (1) | NO863803L (en) |
NZ (1) | NZ217645A (en) |
PT (1) | PT83434B (en) |
SE (4) | SE8604007L (en) |
WO (1) | WO1987002038A1 (en) |
YU (1) | YU46753B (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES8706824A1 (en) * | 1985-04-08 | 1987-07-01 | Genetic Systems Corp | EXPRESSION AND DIAGNOSTIC USE OF gag ENCODED PEPTIDES WHICH ARE IMMUNOLOGICALLY REACTIVE WITH ANTIBODIES TO LAV. |
US4734362A (en) * | 1986-02-03 | 1988-03-29 | Cambridge Bioscience Corporation | Process for purifying recombinant proteins, and products thereof |
US4925784A (en) * | 1986-04-04 | 1990-05-15 | Hoffmann-La Roche Inc. | Expression and purification of an HTLV-III gag/env gene protein |
US4983387A (en) * | 1986-05-19 | 1991-01-08 | Viral Technologies Inc. | HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus |
ES2056054T3 (en) * | 1986-09-19 | 1994-10-01 | Oncogen | USE OF ACTIVATED T-LYMPHOCYTES TO PREPARE A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AIDS. |
IE872748L (en) * | 1986-10-16 | 1988-04-16 | Arjomari Europ | Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells |
JPS63258575A (en) * | 1986-12-15 | 1988-10-26 | レプリゲン コーポレーション | Recombinant hiv envelope protein produced in insect cell |
EP0283327B1 (en) * | 1987-01-16 | 1997-06-25 | Institut Pasteur | Peptides with the immunological properties of HIV-2 |
FR2610632B1 (en) * | 1987-02-11 | 1990-12-21 | Pasteur Institut | CHARACTERISTIC PEPTIDES OF HUMAN IMMUNODEFICIENCY RETROVIRUSES (HIV VIRUSES) THEIR APPLICATIONS IN THE DIAGNOSIS OF INFECTIONS DUE TO CERTAIN OF THESE VIRUSES AND, IF NECESSARY, IN VACCINATION AGAINST AIDS |
US5681713A (en) * | 1987-05-08 | 1997-10-28 | Smithkline Beecham Corporation | Expression of heterologous proteins in Drosophila cells |
GB8714802D0 (en) * | 1987-06-24 | 1987-07-29 | Proteus Biotech Ltd | Synthetic polypeptides |
DE10399031I1 (en) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Recombinant viruses. |
FR2620030B1 (en) * | 1987-09-07 | 1990-03-23 | Transgene Sa | VECTOR FOR THE EXPRESSION OF PROTEINS OF HIV-2 VIRUS, A CAUSAL AGENT FOR AIDS, CELL CULTURE INFECTED OR TRANSFORMED THROUGH THIS VECTOR, PROTEINS OBTAINED, VACCINE AND ANTIBODIES OBTAINED |
IL89118A0 (en) * | 1988-02-03 | 1989-08-15 | Microgenesys Inc | Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1 |
US5763160A (en) * | 1988-02-12 | 1998-06-09 | United Biomedical, Inc. | Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines |
ES2059823T3 (en) * | 1988-05-06 | 1994-11-16 | Ferropas Ag | METHODS AND SYSTEMS FOR PRODUCING HIV ANTIGENS. |
US5043262A (en) * | 1988-05-12 | 1991-08-27 | Dana Farber Cancer Institute | Protein, sequences containing the VPU gene therefore, vectors, methods of preparation and use |
AP129A (en) * | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
US5614404A (en) * | 1988-06-10 | 1997-03-25 | Theriod Biologics, Incorporated | Self-assembled, defective, non-self-propagating lentivirus particles |
US5747324A (en) * | 1988-06-10 | 1998-05-05 | Therion Biologics Corporation | Self-assembled, defective, non-self-propagating lentivirus particles |
US5631154A (en) * | 1988-06-10 | 1997-05-20 | Therion Biologics, Incorporated | Self assembled, defective, non-self-propagating lentivirus particles |
WO1989012095A1 (en) * | 1988-06-10 | 1989-12-14 | Applied Biotechnology, Inc. | A method of evaluating recombinant vaccines against immunodeficiency virus |
US5665577A (en) * | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
DE69031735T2 (en) * | 1989-04-18 | 1998-03-12 | Applied Biotechnology Inc | GENERATION OF HYBRID GENES AND PROTEINS BY RECOMBINATION BY VIRUS |
ES2198400T3 (en) * | 1989-06-01 | 2004-02-01 | Applied Biotechnology, Inc. | VECTOR CODIFYING NON-SELF-PROPAGING, DEFECTIVE, SELF-ASSEMBLED VIRAL PARTICLES. |
GB8923123D0 (en) * | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
US5981276A (en) * | 1990-06-20 | 1999-11-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
US5840312A (en) * | 1991-05-02 | 1998-11-24 | Institut Pasteur | Recombinant Bacillus anthracis strains unable to produce the lethal factor protein or edema factor protein |
FR2676068B1 (en) * | 1991-05-02 | 1994-11-04 | Pasteur Institut | IMMUNOGENIC RECOMBINANT STRAINS OF B. ANTHRACIS - IMMUNOGENIC COMPOSITIONS CONTAINING THEM. |
EP1136562A3 (en) * | 1991-11-08 | 2003-06-25 | PHARMACIA & UPJOHN COMPANY | Feline leukemia virus vaccines |
DE4405810A1 (en) | 1994-02-23 | 1995-08-24 | Behringwerke Ag | Peptides derived from a retrovirus from the HIV group and their use |
AU5259796A (en) | 1995-02-10 | 1996-08-27 | Worcester Foundation For Biomedical Research, Inc. | Delivery of exogenous compounds |
US6013506A (en) * | 1995-06-05 | 2000-01-11 | Wardley; Richard C. | Feline leukemia virus vaccines |
ES2143570T3 (en) * | 1995-09-06 | 2000-05-16 | Schablonentechnik Kufstein Ag | PROCEDURE FOR THE MANUFACTURE OF A SCREENPRINT TEMPLATE. |
US5741492A (en) * | 1996-01-23 | 1998-04-21 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
US6723558B1 (en) | 1996-01-23 | 2004-04-20 | St. Jude Children's Research Hospital | Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses |
US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
US7368102B2 (en) | 2001-12-19 | 2008-05-06 | Nektar Therapeutics | Pulmonary delivery of aminoglycosides |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3485810T2 (en) * | 1983-05-27 | 1992-12-10 | Texas A & M University Syst | METHOD FOR PRODUCING A RECOMBINANT BACULOVIRUS EXPRESSION VECTOR. |
US4662514A (en) * | 1983-11-01 | 1987-05-05 | Charleswater Products, Inc. | Electrically conductive polymeric tubes for static sensitive electronic devices |
US9328391B1 (en) * | 1984-08-22 | 2016-05-03 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Cloning and expression of HIV-1 DNA |
IL76082A (en) * | 1984-08-22 | 1991-07-18 | Us Health | Molecular clones of the genome of htlv-iii and a process for the preparation thereof |
EP0387914B1 (en) * | 1984-10-18 | 1993-08-04 | Institut Pasteur | Envelope antigens of the human immuno-deficiency virus, and their applications |
GB8501473D0 (en) * | 1985-01-21 | 1985-02-20 | Pasteur Institut | Cloned dna sequences |
CA1341423C (en) * | 1984-10-31 | 2003-03-04 | Paul A. Luciw | Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome |
ATE138100T1 (en) * | 1984-12-24 | 1996-06-15 | Genentech Inc | FUSIONS OF AIDS-RELATED POLYPEPTIDES |
US4774175A (en) * | 1985-03-01 | 1988-09-27 | Centocor, Inc. | Immunochemical methods for the detection of antibody against HTLV-III |
NZ215867A (en) * | 1985-04-19 | 1989-10-27 | Hoffmann La Roche | Aids envelope protein, dna vectors and method of production |
FR2586427B1 (en) * | 1985-08-20 | 1988-12-09 | Pasteur Institut | NUCLEOTIDE AND POLYPEPTIDE SEQUENCES FROM VISNA VIRUS AND THEIR APPLICATION TO DIAGNOSTIC TESTS AND THE PRODUCTION OF IMMUNOGENIC COMPOSITIONS |
-
1986
- 1986-09-22 NZ NZ217645A patent/NZ217645A/en unknown
- 1986-09-22 GR GR862412A patent/GR862412B/en unknown
- 1986-09-23 SE SE8604007A patent/SE8604007L/en not_active Application Discontinuation
- 1986-09-23 IE IE252586A patent/IE59314B1/en not_active IP Right Cessation
- 1986-09-24 IT IT67730/86A patent/IT1195829B/en active
- 1986-09-24 GB GB8622987A patent/GB2181435B/en not_active Expired - Fee Related
- 1986-09-24 CH CH3821/86A patent/CH676247A5/fr not_active IP Right Cessation
- 1986-09-24 NO NO863803A patent/NO863803L/en unknown
- 1986-09-24 HU HU864072A patent/HU205780B/en not_active IP Right Cessation
- 1986-09-24 DK DK455486A patent/DK455486A/en not_active Application Discontinuation
- 1986-09-24 FI FI863848A patent/FI863848A/en not_active IP Right Cessation
- 1986-09-24 ES ES8602123A patent/ES2002490A6/en not_active Expired
- 1986-09-25 NL NL8602422A patent/NL8602422A/en not_active Application Discontinuation
- 1986-09-25 FR FR8613414A patent/FR2587720A2/en active Granted
- 1986-09-25 WO PCT/US1986/002002 patent/WO1987002038A1/en active Application Filing
- 1986-09-25 AT AT0256786A patent/ATA256786A/en unknown
- 1986-09-25 DE DE19863690508 patent/DE3690508T1/de not_active Withdrawn
- 1986-09-25 CN CN86106632A patent/CN1020752C/en not_active Expired - Fee Related
- 1986-09-25 PT PT83434A patent/PT83434B/en not_active IP Right Cessation
- 1986-09-25 YU YU165486A patent/YU46753B/en unknown
- 1986-12-31 IL IL8007386A patent/IL80073A/en not_active IP Right Cessation
-
1987
- 1987-09-29 MY MYPI87002188A patent/MY103182A/en unknown
-
1988
- 1988-05-13 ES ES8801494A patent/ES2006941A6/en not_active Expired
-
1991
- 1991-10-14 SE SE9102975A patent/SE9102975L/en not_active Application Discontinuation
- 1991-10-14 SE SE9102976A patent/SE9102976L/en not_active Application Discontinuation
- 1991-10-14 SE SE9102974A patent/SE9102974L/en not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO863803L (en) | Vaccines and Immunoassays for Acquired Immunodeficiency Syndrome (AIDS). | |
SE8701413D0 (en) | EXPRESSION AND PURIFICATION OF AN HTLV-III GAG / ENV GENE PROTEIN | |
DE69535757D1 (en) | RECOMBINANT IMMUNE WEAK EPOXVIRUS | |
DK0584348T3 (en) | Genetic vaccine against immunodeficiency viruses | |
DK33190D0 (en) | HIV-3 RETROVIRUS AND ITS USE | |
DK513388A (en) | PEPTIDES WITH IMMUNOLOGICAL PROPERTIES RESPONSIBLE FOR HIV-2 VIRUSES, NUCLEOTIDE SEQUENCES CODING FOR SUCH PEPTIDES, ANTIGEN AND IMMUNOGENIC AGENTS CONTAINING SUCH PEPTIDES AND PROCEDURES AND HIV KIT TILT INIT | |
NZ219113A (en) | Hiv peptide containing epitope of the env protein | |
ES8700441A1 (en) | Method for the diagnosis of lymphadenopathy and acquired immune depression syndrome. | |
EP0225066A3 (en) | Antigen determinant peptides and a process for the preparation thereof | |
DE3855134D1 (en) | MONOCLONAL HUMAN ANTIBODIES AGAINST HIV-I | |
Verrier et al. | A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates | |
FI885296A (en) | RECOMBINANT HIV-2 POLYPEPTIDES. | |
YOURNO et al. | Nucleotide sequence analysis of the env gene of a new Zairian isolate of HIV-1 | |
EP0327180A3 (en) | Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1 | |
DK172633B1 (en) | A method of preparing a FeLV vaccine and composition and vaccine comprising an inactivated thus produced | |
SE9202934D0 (en) | VACCINES AGAINST MELANOM | |
PT90800A (en) | A PROCESS FOR THE PREPARATION OF PRECURSING ANTIGENS OF THE INVOLVING GLYCOPROTEINS OF A HUMAN HIV-2 RETROVIRUS AND ANTIGENS THAT PRESENT AN IMMULIOUS ANALOGY WITH THESE LAST AND THEIR APPLICATION TO THE DIAGNOSIS | |
DK589586A (en) | EXPRESSION AND DIAGNOSTIC USE OF GAG-CODED PEPTIDES IMMUNOLOGICALLY REACTIVE WITH LOW ANTIBODIES. | |
PT86752A (en) | NEw peptide(s) with immunological properties of HIV-2 envelope protein - have the structure of simian immune deficiency virus proteins, useful in diagnosis and of vaccine components |